Donna M. Papsun
Research Subjects
Donna M. Papsun has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Alex J. Krotulski
Center for Forensic Science Research and Education Fredric Rieders Family Foundation Horsham Pennsylvania USA
9 shared publications - Barry K. Logan
Center for Forensic Science Research and Education Fredric Rieders Family Foundation Horsham Pennsylvania USA
9 shared publications - Michael T. Truver
Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine Forensic Toxicology Laboratory Gainesville, FL 32607
5 shared publications - Melissa F. Fogarty
Center for Forensic Science Research and Education, Fredric Rieders Family Foundation , Horsham, PA 19044
3 shared publications Sara E Walton
Center for Forensic Science Research and Education, Fredric Rieders Family Foundation , Horsham, PA 19044
3 shared publications- Sara E. Walton
Center for Forensic Science Research and Education Fredric Rieders Family Foundation Horsham Pennsylvania USA
3 shared publications
Latest Publications
- Open Access
- 26 September 2026
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 50 (9)
Quantification of kratom alkaloids mitragynine, 7-hydroxy mitragynine, mitragynine pseudoindoxyl, and dihydro-7-hydroxy mitragynine in forensic casework and medicolegal death investigations
Mitragynine (MG) is the primary psychoactive component of the kratom plant (Mitragyna speciosa). 7-Hydroxy mitragynine (7OH-MG) is found naturally in the plant but in small amounts (<2%). MG is metabolized to 7OH-MG and further to mitragynine pseudoindoxyl (MP), with the latter documented via in vitro enzymatic activity. Lack of scheduling and oversight has caused unregulated markets to proliferate with gas stations, smoke shops, and online retailers selling semi-synthetic formulations of these alkaloids under the umbrella term “kratom,” though distinct from botanical kratom. Products containing 7OH-MG, MP, and synthetically derived dihydro-7-hydroxy mitragynine (DH-7OH-MG, aka MGM-15) exhibit greater potencies and activities at the µ-opioid receptor compared to MG and are now highly implicated in intoxications and deaths. These alkaloids present complex analytical and interpretive challenges due to their isomeric forms, incompatibility with certain extraction and instrumental techniques promoting analyte interconversion, instability in blood, and lack of published concentration ranges. A quantitative high-resolution mass spectrometry method for MG, 7OH-MG, MP, and DH-7OH-MG, which prevents interconversion and separates isomers, is presented herein along with stability data and concentrations from more than 200 authentic cases. MG, MP, and DH-7OH-MG were relatively stable in blood, whereas 7OH-MG decreased quickly and by 89% over 112 days with a concurrent increase in MP. In a case subset (n = 139), mean ± SD concentrations in blood were 146 ± 477 ng/ml for 7OH-MG (median: 58 ng/ml, range: 0–5000 ng/ml) and 194 ± 239 ng/ml for MP (median: 120 ng/ml, range: 4.8–1900 ng/ml). In a second subset (n = 17), the mean ± SD DH-7OH-MG (MGM-15) concentration was 324 ± 669 ng/ml (median: 170 ng/ml, range: 50–2900 ng/ml). Testing for kratom alkaloids is currently extremely limited and/or subject to potential inaccuracies due to interconversion, leaving adverse events and fatalities under-investigated. Continued vigilance is needed as the kratom alkaloid product landscape rapidly evolves.
- 26 September 2026
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 50 (9)
Open AccessQuantification of kratom alkaloids mitragynine, 7-hydroxy mitragynine, mitragynine pseudoindoxyl, and dihydro-7-hydroxy mitragynine in forensic casework and medicolegal death investigations
Mitragynine (MG) is the primary psychoactive component of the kratom plant (Mitragyna speciosa). 7-Hydroxy mitragynine (7OH-MG) is found naturally in the plant but in small amounts (<2%). MG is metabolized to 7OH-MG and further to mitragynine pseudoindoxyl (MP), with the latter documented via in vitro enzymatic activity. Lack of scheduling and oversight has caused unregulated markets to proliferate with gas stations, smoke shops, and online retailers selling semi-synthetic formulations of these alkaloids under the umbrella term “kratom,” though distinct from botanical kratom. Products containing 7OH-MG, MP, and synthetically derived dihydro-7-hydroxy mitragynine (DH-7OH-MG, aka MGM-15) exhibit greater potencies and activities at the µ-opioid receptor compared to MG and are now highly implicated in intoxications and deaths. These alkaloids present complex analytical and interpretive challenges due to their isomeric forms, incompatibility with certain extraction and instrumental techniques promoting analyte interconversion, instability in blood, and lack of published concentration ranges. A quantitative high-resolution mass spectrometry method for MG, 7OH-MG, MP, and DH-7OH-MG, which prevents interconversion and separates isomers, is presented herein along with stability data and concentrations from more than 200 authentic cases. MG, MP, and DH-7OH-MG were relatively stable in blood, whereas 7OH-MG decreased quickly and by 89% over 112 days with a concurrent increase in MP. In a case subset (n = 139), mean ± SD concentrations in blood were 146 ± 477 ng/ml for 7OH-MG (median: 58 ng/ml, range: 0–5000 ng/ml) and 194 ± 239 ng/ml for MP (median: 120 ng/ml, range: 4.8–1900 ng/ml). In a second subset (n = 17), the mean ± SD DH-7OH-MG (MGM-15) concentration was 324 ± 669 ng/ml (median: 170 ng/ml, range: 50–2900 ng/ml). Testing for kratom alkaloids is currently extremely limited and/or subject to potential inaccuracies due to interconversion, leaving adverse events and fatalities under-investigated. Continued vigilance is needed as the kratom alkaloid product landscape rapidly evolves.
- 11 September 2026
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 50 (9)
Intoxications and fatalities associated with the ingestion of the novel synthetic cathinone, N -isopropyl butylone
Synthetic cathinones represent an expanding class of novel psychoactive substances (NPS), with their proliferation largely driven by international drug control measures and the rapid cycling of structural analogues designed to circumvent legislative scheduling. Following the international control of N, N-dimethylpentylone (DMP) in 2024, N-isopropyl butylone (NiPB) was increasingly detected in forensic toxicological casework as the prevalence of DMP declined. However, limited data currently exist regarding NiPB’s concentration ranges in forensic investigations. This report describes a validated liquid chromatography-tandem quadrupole mass spectrometry (LC-QQQ-MS) method for the quantitation of NiPB in biological specimens, which was applied to the analysis of drugged driving (n = 1) and postmortem (n = 15) cases. The driving under the influence of drugs case yielded a NiPB blood concentration of 16 ng/mL, whereas the remaining 15 cases demonstrated blood concentrations ranging from <1 to 1400 ng/mL. For one case, NiPB was quantitated in blood, vitreous fluid, and urine, with concentrations of 18, 17, and 2200 ng/mL, respectively. Polydrug use was observed for all cases and frequently involved fentanyl (75%), cocaine and/or methamphetamine (69%), other synthetic cathinones (25%), ethanol (31%), and additional NPS such as bromazolam (19%) and MDMB-4en-PINACA (13%). Concentrations overlapped between antemortem and postmortem cases and were comparable to those reported for structurally related beta-keto methylenedioxyamphetamines, suggesting that members of this analogue class may share similar patterns of use and toxicological profiles. Although NiPB was identified as a contributing factor in several fatalities, the lack of pharmacological and toxicological data limits further interpretation of measured concentrations and the extent of its contribution to these fatal outcomes. Additional studies incorporating paired central and peripheral blood specimens are warranted to better characterize potential postmortem redistribution and its impact on NiPB blood concentration interpretation. Overall, this case series addresses a critical literature gap on NiPB by providing analytical and interpretive data to support forensic laboratories as NiPB identifications increase within the evolving NPS stimulant market.
- 11 September 2026
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 50 (9)
Intoxications and fatalities associated with the ingestion of the novel synthetic cathinone, N -isopropyl butylone
Synthetic cathinones represent an expanding class of novel psychoactive substances (NPS), with their proliferation largely driven by international drug control measures and the rapid cycling of structural analogues designed to circumvent legislative scheduling. Following the international control of N, N-dimethylpentylone (DMP) in 2024, N-isopropyl butylone (NiPB) was increasingly detected in forensic toxicological casework as the prevalence of DMP declined. However, limited data currently exist regarding NiPB’s concentration ranges in forensic investigations. This report describes a validated liquid chromatography-tandem quadrupole mass spectrometry (LC-QQQ-MS) method for the quantitation of NiPB in biological specimens, which was applied to the analysis of drugged driving (n = 1) and postmortem (n = 15) cases. The driving under the influence of drugs case yielded a NiPB blood concentration of 16 ng/mL, whereas the remaining 15 cases demonstrated blood concentrations ranging from <1 to 1400 ng/mL. For one case, NiPB was quantitated in blood, vitreous fluid, and urine, with concentrations of 18, 17, and 2200 ng/mL, respectively. Polydrug use was observed for all cases and frequently involved fentanyl (75%), cocaine and/or methamphetamine (69%), other synthetic cathinones (25%), ethanol (31%), and additional NPS such as bromazolam (19%) and MDMB-4en-PINACA (13%). Concentrations overlapped between antemortem and postmortem cases and were comparable to those reported for structurally related beta-keto methylenedioxyamphetamines, suggesting that members of this analogue class may share similar patterns of use and toxicological profiles. Although NiPB was identified as a contributing factor in several fatalities, the lack of pharmacological and toxicological data limits further interpretation of measured concentrations and the extent of its contribution to these fatal outcomes. Additional studies incorporating paired central and peripheral blood specimens are warranted to better characterize potential postmortem redistribution and its impact on NiPB blood concentration interpretation. Overall, this case series addresses a critical literature gap on NiPB by providing analytical and interpretive data to support forensic laboratories as NiPB identifications increase within the evolving NPS stimulant market.
- 24 April 2026
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 50 (6)
An enduring threat: NPS benzodiazepines in forensic and clinical toxicology from 2021 to 2025
The proliferation and sustained detection of novel psychoactive benzodiazepines in forensic and clinical toxicology, combined with their potential for adverse events, poses an enduring threat to public health and safety with complex characteristics and challenges unique from other subclasses of novel psychoactive substances (NPS). This study aimed to systematically review the published effects, observations, and toxicological data from postmortem and human performance studies [including clinical, driving under the influence of drugs (DUID), and drug-facilitated crimes (DFC)] involving NPS benzodiazepines from 2021 to 2025. The challenges this class of compounds presents to clinicians, toxicologists, and medical professionals were also addressed, including both analytical and interpretative challenges. Literature reviews were performed in PubMed, Google Scholar, Google Search, toxicology journals, and conference abstract proceedings using search terms such as “NPS benzodiazepines,” “designer benzodiazepines,” and compound specific searches; authoritative websites such as NPS Discovery, National Forensic Laboratory Information System, and the European Union Drug Agency were also consulted. A total of 259 NPS benzodiazepine-related studies were identified including 29 postmortem, 15 DUID, 27 clinical, and 5 DFC studies detailed in this review. NPS benzodiazepines were widely pervasive in both postmortem and human performance cases with overlapping toxic and recreational concentrations; often involving polysubstance use with other central nervous system depressants and stimulants. Unique clinical presentations, observed effects, and autopsy findings were also reported for NPS benzodiazepines. This review provides an updated, consolidated resource to support toxicologists and clinicians in interpretation, emerging risk assessment, and evolving challenges associated with NPS benzodiazepines across postmortem and human performance settings.
- 24 April 2026
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 50 (6)
An enduring threat: NPS benzodiazepines in forensic and clinical toxicology from 2021 to 2025
The proliferation and sustained detection of novel psychoactive benzodiazepines in forensic and clinical toxicology, combined with their potential for adverse events, poses an enduring threat to public health and safety with complex characteristics and challenges unique from other subclasses of novel psychoactive substances (NPS). This study aimed to systematically review the published effects, observations, and toxicological data from postmortem and human performance studies [including clinical, driving under the influence of drugs (DUID), and drug-facilitated crimes (DFC)] involving NPS benzodiazepines from 2021 to 2025. The challenges this class of compounds presents to clinicians, toxicologists, and medical professionals were also addressed, including both analytical and interpretative challenges. Literature reviews were performed in PubMed, Google Scholar, Google Search, toxicology journals, and conference abstract proceedings using search terms such as “NPS benzodiazepines,” “designer benzodiazepines,” and compound specific searches; authoritative websites such as NPS Discovery, National Forensic Laboratory Information System, and the European Union Drug Agency were also consulted. A total of 259 NPS benzodiazepine-related studies were identified including 29 postmortem, 15 DUID, 27 clinical, and 5 DFC studies detailed in this review. NPS benzodiazepines were widely pervasive in both postmortem and human performance cases with overlapping toxic and recreational concentrations; often involving polysubstance use with other central nervous system depressants and stimulants. Unique clinical presentations, observed effects, and autopsy findings were also reported for NPS benzodiazepines. This review provides an updated, consolidated resource to support toxicologists and clinicians in interpretation, emerging risk assessment, and evolving challenges associated with NPS benzodiazepines across postmortem and human performance settings.
- 10 March 2026
- Published by Elsevier in Forensic Science International
- Vol. 384, 112917
Case series involving the synthetic cathinones alpha-PHP, alpha-PiHP, MDPHP, and MDPiHP in forensic investigations
- 10 March 2026
- Published by Elsevier in Forensic Science International
- Vol. 384, 112917
Case series involving the synthetic cathinones alpha-PHP, alpha-PiHP, MDPHP, and MDPiHP in forensic investigations
- 30 June 2025
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 49 (8) , 603-608
Drug identification in biologicals on clothing, bedding, and other materials
Toxicology testing is an integral component of postmortem, drug-facilitated crime, and driving under the influence investigations. Recommendations pertaining to traditional matrices, sample amounts, and collection container types are well documented in the literature and guidance documents. However, not all cases have traditional toxicological specimens available (e.g. blood with a fluoride additive), and thus require nontraditional toxicology test options. In these cases, a forensic laboratory is contacted to determine if nontraditional objects, such as clothing, bedding, automotive, personal hygiene, or household items, stained with biological material, are suitable for analysis. Comprehensive method validation, as required for routine toxicology tests, is not practical to complete for these items, but this should not deter the toxicology laboratory from taking on this work. Herein, we describe a developed and implemented process for qualitative analysis of biological fluids on/in objects, which ensures the robustness and reliability of reported results. The specific procedures used, which include sample preparation, the incorporation of specialized quality control samples made from the items themselves, analytical acceptance criteria, and reporting considerations are thoroughly detailed. Positive findings from cases were obtained for a variety of drugs, encompassing illicit, prescription, novel psychoactive substances, and over-the-counter medications. Some examples include identification of zolpidem from vomit on clothing; cocaine, cocaine metabolites, levamisole, codeine, acetaminophen, and caffeine in stains on bedding; and diphenhydramine, doxylamine, and dextromethorphan in stains on a mattress pad cover. This methodology is fit-for-purpose and suitable for the toxicological investigation of these unique specimens without any significant limitations. This testing process may be used to identify past drug exposure, associate drug exposure to a particular location or scene, and/or provide insight into an event when a missing person has not been found.
- 30 June 2025
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 49 (8) , 603-608
Drug identification in biologicals on clothing, bedding, and other materials
Toxicology testing is an integral component of postmortem, drug-facilitated crime, and driving under the influence investigations. Recommendations pertaining to traditional matrices, sample amounts, and collection container types are well documented in the literature and guidance documents. However, not all cases have traditional toxicological specimens available (e.g. blood with a fluoride additive), and thus require nontraditional toxicology test options. In these cases, a forensic laboratory is contacted to determine if nontraditional objects, such as clothing, bedding, automotive, personal hygiene, or household items, stained with biological material, are suitable for analysis. Comprehensive method validation, as required for routine toxicology tests, is not practical to complete for these items, but this should not deter the toxicology laboratory from taking on this work. Herein, we describe a developed and implemented process for qualitative analysis of biological fluids on/in objects, which ensures the robustness and reliability of reported results. The specific procedures used, which include sample preparation, the incorporation of specialized quality control samples made from the items themselves, analytical acceptance criteria, and reporting considerations are thoroughly detailed. Positive findings from cases were obtained for a variety of drugs, encompassing illicit, prescription, novel psychoactive substances, and over-the-counter medications. Some examples include identification of zolpidem from vomit on clothing; cocaine, cocaine metabolites, levamisole, codeine, acetaminophen, and caffeine in stains on bedding; and diphenhydramine, doxylamine, and dextromethorphan in stains on a mattress pad cover. This methodology is fit-for-purpose and suitable for the toxicological investigation of these unique specimens without any significant limitations. This testing process may be used to identify past drug exposure, associate drug exposure to a particular location or scene, and/or provide insight into an event when a missing person has not been found.
- 8 May 2025
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 49 (8) , 551-558
Medetomidine quantitation and enantiomer differentiation in biological specimens collected after fatal and non-fatal opioid overdoses
Medetomidine is an alpha-2 agonist and non-opioid sedative. Its presence in illicit fentanyl and heroin drug supplies poses significant risks to user health caused by cardiac effects and sedation. Medetomidine exists in two enantiomeric forms: dexmedetomidine and levomedetomidine. Dexmedetomidine is used in humans in medical settings, while dexmedetomidine alone and a racemic mixture of dexmedetomidine and levomedetomidine are used in animals in veterinary settings. Little information is known about circulating blood concentrations of medetomidine or its enantiomers in humans in situations involving synthetic opioids (e.g. fentanyl) and other sedatives (e.g. xylazine, benzodiazepines). A new toxicological workflow using liquid chromatography–tandem quadrupole mass spectrometry (LC–QQQ-MS) was developed and validated for the quantitation of medetomidine and the qualitative enantiomeric separation of dexmedetomidine and levomedetomidine. The assays were applied to a case series of 100 authentic specimens from emergency department admissions and forensic postmortem investigations containing medetomidine, fentanyl, xylazine, and metabolites, among other substances. Medetomidine blood concentrations in non-fatal overdoses ranged 0.1–16 ng/mL (median: 1.5 ng/mL) and in fatal overdoses ranged 0.1–32 ng/mL (median: 0.31 ng/mL). Xylazine was co-detected in 76% of cases with higher median concentrations: 8.3 ng/mL (non-fatal) and 15 ng/mL (fatal). Fentanyl was co-detected in 93% of cases with median concentrations of 5.2 ng/mL (non-fatal) and 21 ng/mL (fatal). Dexmedetomidine and levomedetomidine were identified in 90% of cases; the remaining cases were confirmed or suspected medical-setting administration of dexmedetomidine. These findings demonstrate that medetomidine is arising from veterinary or clandestine sources, and we hypothesize the latter. Recreational medetomidine use causes adverse effects such as profound bradycardia and heightened sedation, especially when combined with fentanyl and xylazine. Forensic laboratories must remain aware of adulterants, like medetomidine, appearing in traditional opioid products (e.g. fentanyl, heroin), updating testing methods to capture these emerging adulterants in real-time.
- 8 May 2025
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 49 (8) , 551-558
Medetomidine quantitation and enantiomer differentiation in biological specimens collected after fatal and non-fatal opioid overdoses
Medetomidine is an alpha-2 agonist and non-opioid sedative. Its presence in illicit fentanyl and heroin drug supplies poses significant risks to user health caused by cardiac effects and sedation. Medetomidine exists in two enantiomeric forms: dexmedetomidine and levomedetomidine. Dexmedetomidine is used in humans in medical settings, while dexmedetomidine alone and a racemic mixture of dexmedetomidine and levomedetomidine are used in animals in veterinary settings. Little information is known about circulating blood concentrations of medetomidine or its enantiomers in humans in situations involving synthetic opioids (e.g. fentanyl) and other sedatives (e.g. xylazine, benzodiazepines). A new toxicological workflow using liquid chromatography–tandem quadrupole mass spectrometry (LC–QQQ-MS) was developed and validated for the quantitation of medetomidine and the qualitative enantiomeric separation of dexmedetomidine and levomedetomidine. The assays were applied to a case series of 100 authentic specimens from emergency department admissions and forensic postmortem investigations containing medetomidine, fentanyl, xylazine, and metabolites, among other substances. Medetomidine blood concentrations in non-fatal overdoses ranged 0.1–16 ng/mL (median: 1.5 ng/mL) and in fatal overdoses ranged 0.1–32 ng/mL (median: 0.31 ng/mL). Xylazine was co-detected in 76% of cases with higher median concentrations: 8.3 ng/mL (non-fatal) and 15 ng/mL (fatal). Fentanyl was co-detected in 93% of cases with median concentrations of 5.2 ng/mL (non-fatal) and 21 ng/mL (fatal). Dexmedetomidine and levomedetomidine were identified in 90% of cases; the remaining cases were confirmed or suspected medical-setting administration of dexmedetomidine. These findings demonstrate that medetomidine is arising from veterinary or clandestine sources, and we hypothesize the latter. Recreational medetomidine use causes adverse effects such as profound bradycardia and heightened sedation, especially when combined with fentanyl and xylazine. Forensic laboratories must remain aware of adulterants, like medetomidine, appearing in traditional opioid products (e.g. fentanyl, heroin), updating testing methods to capture these emerging adulterants in real-time.
- 27 January 2025
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 49 (3) , 143-151
Toxicological evaluation, postmortem case descriptions, and pharmacological activity of N,N-dimethylpentylone and related analogs
Identification of N,N-dimethylpentylone (DMP) in counterfeit “Ecstasy” and “Molly” tablets poses risk to public health due to its adverse effects. Little information is available regarding the pharmacological activity or relevant blood or tissue concentrations of DMP, and even less is known about other structurally related beta-keto methylenedioxyamphetamine analogs on recreational drug markets, such as N-propyl butylone. Here, a novel toxicological assay utilizing liquid chromatography–tandem quadrupole mass spectrometry was developed and validated for the quantitation of DMP and five related synthetic cathinones [eutylone, pentylone, N-ethyl pentylone (NEP), N-propyl butylone, and N-cyclohexyl butylone], with chromatographic resolution from isomeric variants and quantitation performed by standard addition. A forensic series of 125 cases is presented for DMP and related analogs, along with pharmacological activity assessments using monoamine transporter and mouse behavioral assays. The blood concentration range for DMP in postmortem forensic cases was 3.3–4600 ng/mL (mean: 320 ± 570 ng/mL, median: 150 ng/mL), whereas pentylone, the primary N-desmethyl metabolite of DMP, was identified in 98% of cases with a concentration range 1.3–710 ng/mL (mean ± SD: 105 ± 120 ng/mL, median: 71 ng/mL). N-Propyl butylone, a newly identified synthetic cathinone, was quantitated in seven cases (mean ± SD: 82 ± 75 ng/mL, median: 50 ng/mL, range: 1.7–200 ng/mL). DMP displayed potent uptake inhibition at the dopamine transporter [half maximal inhibitory concentration (IC50) of 49 nM], with 100-fold weaker potency at the serotonin transporter (IC50 = 4990 nM). DMP was a locomotor stimulant in mice [medium effective dose (ED50) of 3.5 mg/kg] exhibiting potency relatively similar to eutylone, NEP, and pentylone. Our results show that DMP is a psychomotor stimulant associated with adverse clinical outcomes leading to death. Forensic laboratories must continue to update testing methods to capture emerging drugs, with specific emphasis on resolution and identification of isomeric species. Following the scheduling of DMP in early 2024, there could be an anticipated market shift toward a new unregulated synthetic stimulant to replace DMP.
- 27 January 2025
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 49 (3) , 143-151
Toxicological evaluation, postmortem case descriptions, and pharmacological activity of N,N-dimethylpentylone and related analogs
Identification of N,N-dimethylpentylone (DMP) in counterfeit “Ecstasy” and “Molly” tablets poses risk to public health due to its adverse effects. Little information is available regarding the pharmacological activity or relevant blood or tissue concentrations of DMP, and even less is known about other structurally related beta-keto methylenedioxyamphetamine analogs on recreational drug markets, such as N-propyl butylone. Here, a novel toxicological assay utilizing liquid chromatography–tandem quadrupole mass spectrometry was developed and validated for the quantitation of DMP and five related synthetic cathinones [eutylone, pentylone, N-ethyl pentylone (NEP), N-propyl butylone, and N-cyclohexyl butylone], with chromatographic resolution from isomeric variants and quantitation performed by standard addition. A forensic series of 125 cases is presented for DMP and related analogs, along with pharmacological activity assessments using monoamine transporter and mouse behavioral assays. The blood concentration range for DMP in postmortem forensic cases was 3.3–4600 ng/mL (mean: 320 ± 570 ng/mL, median: 150 ng/mL), whereas pentylone, the primary N-desmethyl metabolite of DMP, was identified in 98% of cases with a concentration range 1.3–710 ng/mL (mean ± SD: 105 ± 120 ng/mL, median: 71 ng/mL). N-Propyl butylone, a newly identified synthetic cathinone, was quantitated in seven cases (mean ± SD: 82 ± 75 ng/mL, median: 50 ng/mL, range: 1.7–200 ng/mL). DMP displayed potent uptake inhibition at the dopamine transporter [half maximal inhibitory concentration (IC50) of 49 nM], with 100-fold weaker potency at the serotonin transporter (IC50 = 4990 nM). DMP was a locomotor stimulant in mice [medium effective dose (ED50) of 3.5 mg/kg] exhibiting potency relatively similar to eutylone, NEP, and pentylone. Our results show that DMP is a psychomotor stimulant associated with adverse clinical outcomes leading to death. Forensic laboratories must continue to update testing methods to capture emerging drugs, with specific emphasis on resolution and identification of isomeric species. Following the scheduling of DMP in early 2024, there could be an anticipated market shift toward a new unregulated synthetic stimulant to replace DMP.
- 28 August 2024
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 48 (9) , 653-658
Bromazolam in impaired driving investigations
The designer benzodiazepine bromazolam is increasingly encountered in forensic casework, including impaired driving investigations. A series of suspected impaired driving cases that tested positive for bromazolam are described herein along with information about driving performance, driver appearance, and observed behavior. Bromazolam was indicated in casework either through screening by liquid chromatography–time of flight mass spectrometry (LC–TOF-MS) and/or a positive benzodiazepine immunoassay screen. Blood samples were forwarded for quantitative confirmatory analysis using a liquid chromatography–tandem mass spectrometry (LC–MS–MS) method with a reporting limit of 2.0 ng/mL. Bromazolam was reported in 98 impaired driving cases from samples reported between January 2021 and December 2023, with the earliest detection from September 2020. Mean and median blood concentrations were 125 ± 145 and 84 ng/mL respectively, with a range of 4.2–990 ng/mL. Additional positive findings were reported in almost all cases, with the highest result (990 ng/mL) being the only case in which bromazolam was the only finding. Fentanyl was the most frequent drug found in combination with bromazolam. Driving behaviors reported in these cases included erratic driving, errors in Standardized Field Sobriety Tests, and symptoms consistent with central nervous system depressants, including slurred speech, incoordination, and lethargic behavior. Based on its prevalence and demonstrated impairing effects, bromazolam should be included in the scope of impaired driving testing as long as it continues to be prevalent in the drug supply.
- 28 August 2024
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 48 (9) , 653-658
Bromazolam in impaired driving investigations
The designer benzodiazepine bromazolam is increasingly encountered in forensic casework, including impaired driving investigations. A series of suspected impaired driving cases that tested positive for bromazolam are described herein along with information about driving performance, driver appearance, and observed behavior. Bromazolam was indicated in casework either through screening by liquid chromatography–time of flight mass spectrometry (LC–TOF-MS) and/or a positive benzodiazepine immunoassay screen. Blood samples were forwarded for quantitative confirmatory analysis using a liquid chromatography–tandem mass spectrometry (LC–MS–MS) method with a reporting limit of 2.0 ng/mL. Bromazolam was reported in 98 impaired driving cases from samples reported between January 2021 and December 2023, with the earliest detection from September 2020. Mean and median blood concentrations were 125 ± 145 and 84 ng/mL respectively, with a range of 4.2–990 ng/mL. Additional positive findings were reported in almost all cases, with the highest result (990 ng/mL) being the only case in which bromazolam was the only finding. Fentanyl was the most frequent drug found in combination with bromazolam. Driving behaviors reported in these cases included erratic driving, errors in Standardized Field Sobriety Tests, and symptoms consistent with central nervous system depressants, including slurred speech, incoordination, and lethargic behavior. Based on its prevalence and demonstrated impairing effects, bromazolam should be included in the scope of impaired driving testing as long as it continues to be prevalent in the drug supply.
- 5 August 2024
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 48 (8) , 550-556
Elucidating the potential role of microorganisms in postmortem biotransformation: a comparison of clonazolam and its metabolite in postmortem and DUID cases
Clonazolam is a designer triazolobenzodiazepine first synthesized in 1971 and primarily used for its anxiolytic and sedative effects. It became a drug of misuse in 2012 and is known for its high potency and long duration of effects. Previous studies of nitrobenzodiazepines such as nitrazepam, clonazepam, flunitrazepam, and their metabolites have demonstrated that bacterial species native to the gastrointestinal tract and active during postmortem (PM) decomposition are capable of affecting positivity and compound-to-metabolite ratios. Further studies have not been performed with clonazolam; however, it possesses the nitro functional group necessary for this biotransformation. To understand whether clonazolam may be similarly affected, PM (n = 288) and driving under the influence of drugs (DUID, n = 54) cases positive for 8-aminoclonazolam reported by NMS Labs from 2020 to 2023 were selected for inclusion in this study. Concentrations of clonazolam and 8-aminoclonazolam were evaluated, and concurrent identification of parent drug and metabolite occurred less frequently in PM cases (n = 1, 0.30% of cases) than in DUID cases (n = 21, 38% of cases). The clonazolam concentration in one PM case was 13 ng/mL. In DUID cases the median clonazolam concentration was 4.0 ng/mL and ranged from 2.0-10 ng/mL. 8-Aminoclonazolam had median concentrations of 13 and 19 ng/mL and ranges of 2.0-580 and 2.8-59 ng/mL for PM and DUID cases, respectively. Due to the everchanging landscape of the DBZD market, in vitro studies of PM microbial biotransformation of clonazolam are unavailable. The data reported herein provide valuable information in the absence of such studies and represent an alternative method of investigating this phenomenon as a potential cause of parent nitrobenzodiazepine to metabolite conversion.
- 5 August 2024
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 48 (8) , 550-556
Elucidating the potential role of microorganisms in postmortem biotransformation: a comparison of clonazolam and its metabolite in postmortem and DUID cases
Clonazolam is a designer triazolobenzodiazepine first synthesized in 1971 and primarily used for its anxiolytic and sedative effects. It became a drug of misuse in 2012 and is known for its high potency and long duration of effects. Previous studies of nitrobenzodiazepines such as nitrazepam, clonazepam, flunitrazepam, and their metabolites have demonstrated that bacterial species native to the gastrointestinal tract and active during postmortem (PM) decomposition are capable of affecting positivity and compound-to-metabolite ratios. Further studies have not been performed with clonazolam; however, it possesses the nitro functional group necessary for this biotransformation. To understand whether clonazolam may be similarly affected, PM (n = 288) and driving under the influence of drugs (DUID, n = 54) cases positive for 8-aminoclonazolam reported by NMS Labs from 2020 to 2023 were selected for inclusion in this study. Concentrations of clonazolam and 8-aminoclonazolam were evaluated, and concurrent identification of parent drug and metabolite occurred less frequently in PM cases (n = 1, 0.30% of cases) than in DUID cases (n = 21, 38% of cases). The clonazolam concentration in one PM case was 13 ng/mL. In DUID cases the median clonazolam concentration was 4.0 ng/mL and ranged from 2.0-10 ng/mL. 8-Aminoclonazolam had median concentrations of 13 and 19 ng/mL and ranges of 2.0-580 and 2.8-59 ng/mL for PM and DUID cases, respectively. Due to the everchanging landscape of the DBZD market, in vitro studies of PM microbial biotransformation of clonazolam are unavailable. The data reported herein provide valuable information in the absence of such studies and represent an alternative method of investigating this phenomenon as a potential cause of parent nitrobenzodiazepine to metabolite conversion.